Navigation Links
Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
Date:12/10/2007

ATLANTA - Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

The two patients who had relapsed after the treatment regained a complete response after additional therapy.

"Our results show that this approach may actually be curative of follicular lymphoma," says lead author Issa Khouri, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation. "No other treatments produce this type of response."

The traditional treatment before receiving a matched stem cell donation consists of higher-dose chemotherapy that kills the lymphoma cells and shuts down the patient's own blood-producing stem cells - a process called myeloablation. While waiting for the donor's stem cells to engraft in the bone marrow and to begin producing blood, patients are vulnerable to infection, bleeding, and anemia.

Early research by Khouri and colleagues indicated that using a nonmyeloablative chemotherapy approach could control the lymphoma while sparing patients the side effects of high-dose chemotherapy. The transplanted blood stem cells launch an immune system attack on the lymphoma, a process called graft-vs.-lymphoma immunity.

"Our early results were encouraging. But with follicular lymphoma you need a long follow-up to see if the results hold," Khouri says. "This disease tends to recur later on, sometimes years after chemotherapy."

All patients in the present trial have been followed for at least five years, some for up to nine years. Trial patients had received 2 to 7 different chemotherapy regimens. Eight had received transplants of their own stem cells. At transplantation, 29 were in partial remission and 18 were in complete remission.

All 47 achieved complete remission after receiving matched blood stem cells from donors. One patient relapsed at 18 months. After receiving a donor lymphocyte infusion, the patient began a continuous complete response at 24 months. The other patient relapsed at 20 months and was found to have graft failure. Since treatment with rituximab, this patient has been in complete remission for four years.

Seven patients died during the trial, none from follicular lymphoma, Khouri notes. The 40 remaining patients all remain in remission. Overall survival at six years is 85 percent and current progression-free survival is 83 percent.

Acute graft-vs.-host disease (GVHD) arose in 11 percent of patients. Another 51 percent had chronic graft-vs.-host disease. GVHD was treated with immunosuppressive therapy. Khouri notes that only five patients in the study group remain on immunosuppressive therapy.

Long-term follow-up also allowed researchers to thoroughly gauge side effects, or toxicity, of the non-myeloablative approach. "It reduces toxicity significantly," Khouri says. "Even elderly patients can have this done."

Patients received fludarabine, cyclophosphamide and rituximab for three days before transplantation. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease.

Follicular lymphoma is a Non-Hodgkin lymphoma, with about 12,000 new cases diagnosed annually.


'/>"/>

Contact: Scott Merville
sdmervil@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. Medicare modernization act did not change chemotherapy as feared
8. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
9. Cancer conflict with chemotherapy treatment
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2017)... City, FL (PRWEB) , ... May 28, 2017 , ... ... be treated with Nerve-Express, the latest Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, ... heart rate and R-R interval, indicating the state of a patient’s autonomic nervous system ...
(Date:5/28/2017)... FL (PRWEB) , ... May 28, 2017 , ... ... of America (PPOA), is proud to announce that Sheldon K. Cho, MD, has ... interventional pain management, a specialty that concentrates on minimally invasive techniques to treat ...
(Date:5/27/2017)... TX (PRWEB) , ... May 27, 2017 , ... Hate visiting the dentist? You should ... you'll need to take care of your teeth at home. Here are some dental tips ... after meals. Keep a small toothbrush in your work desk or a locker at school ...
(Date:5/27/2017)... ... 27, 2017 , ... Most us are familiar with the sound of occasional ... the Osteoarthritis Initiative shows that certain people who experience consistent joint popping, grating ... give doctors the opportunity to treat patients before the problem becomes pronounced, potentially hedging ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: ... Inc. ("WRB"), a health care service center company ... WRB specializes in relationship management programs for leading ... WRB will join Envoy ... support services for manufacturers, biotech firms, and other service ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
Breaking Medicine Technology: